Sign in

You're signed outSign in or to get full access.

FI

Forian Inc. (FORA)·Q3 2025 Earnings Summary

Executive Summary

  • Q3 2025 revenue grew 66% year over year to $7.76M, with adjusted EBITDA improving to $0.47M; net loss narrowed to $0.15M and basic/diluted EPS reported as $0.00 .
  • Forian delivered a revenue and EPS beat versus S&P Global consensus: revenue $7.76M vs $7.26M estimate; EPS +$0.021 vs -$0.04 estimate (single analyst coverage) — a meaningful upside surprise; management reiterated finishing FY25 at the high end of prior ranges for both revenue and adjusted EBITDA .
  • Operationally, growth was driven by Kyber Data Science contributions (~$2M of the YoY increase) and organic expansion in HEOR/data solutions; convertible notes matured and were fully repaid on Sept 1, reducing interest expense and simplifying the balance sheet .
  • The quarter added catalysts around estimate revisions and narrative momentum: sustained multi-quarter revenue progress (Q1–Q3), high-end guidance bias, and improved operating leverage; management maintained focus on selective data investments and M&A while noting mixed end-market spending environments .

What Went Well and What Went Wrong

What Went Well

  • Revenue beat and strong YoY growth: $7.76M (+66% YoY), aided by Kyber Data Science and HEOR expansions; adjusted EBITDA rose to $0.47M, evidencing operating leverage .
  • Balance sheet progress: fully repaid the remaining $6.8M principal and accrued interest on convertible notes at maturity (Sept 1), with $28.2M cash and marketable securities at quarter-end supporting growth investments .
  • Management confidence and strategic execution: “another solid quarter characterized by disciplined execution, expanding client engagement, and ongoing operational improvement,” with reiterated expectation to finish FY25 at the high end of guidance .

What Went Wrong

  • Sequential margin/earnings mixed: operating loss remained ($0.47M), and company-reported EPS rounded to $0.00 despite net loss; higher data costs and inclusion of Kyber expenses are headwinds to margin progression .
  • End-market caution persists: pharma spending cautious amid macro/geopolitical shifts; guidance range remains wide given renewal timing and discretionary strategic investments that can affect near-term adjusted EBITDA .
  • Limited disclosure depth: no segment revenue breakdown provided; reliance on non-GAAP (Adjusted EBITDA) remains high, with notable recurring exclusions (stock comp, data costs, and litigation/transaction items) .

Financial Results

Consolidated P&L and Non-GAAP

MetricQ3 2024Q1 2025Q2 2025Q3 2025
Revenue ($USD)$4,686,312 $7,056,116 $7,476,140 $7,762,183
Net Income ($USD)$(204,907) $(1,125,862) $224,793 $(151,220)
EPS (Basic/Diluted $USD)$(0.01) $(0.04) $0.01 $0.00
Adjusted EBITDA ($USD)$185,916 $(50,778) $591,073 $470,645

Notes: Company EPS reflects rounding to $0.00 in Q3 alongside a GAAP net loss .

Estimates vs Actuals (S&P Global)

MetricQ3 2025 EstimateQ3 2025 Actual
Revenue ($USD)$7,264,000*$7,762,183
Primary EPS ($USD)-$0.04*$0.0206*

Values retrieved from S&P Global.*

KPIs and Balance Sheet Highlights

KPIQ1 2025Q2 2025Q3 2025
Cash + Marketable Securities ($USD)$35.7M $35.6M $28.2M
Working Capital ($USD)——$29.2M
Convertible Notes Outstanding/Status$6.8M due Sept 2025 $6.8M due Sept 2025 Fully repaid at maturity

Segment breakdown: Not disclosed in press release or call materials .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
RevenueFY 2025$28–$30M (Q1, Q2 reaffirmations) Finish at higher end of $28–$30M Maintained; upward bias
Adjusted EBITDAFY 2025-$1.0M to +$1.0M (Q1, Q2) Finish at higher end of -$1.0M to +$1.0M Maintained; upward bias

Management reiterated the high-end finish for both revenue and adjusted EBITDA following the Q3 beat and sustained execution .

Earnings Call Themes & Trends

TopicPrevious Mentions (Q1 2025)Previous Mentions (Q2 2025)Current Period (Q3 2025)Trend
Kyber Data Science impact1-year SaaS contracts; top-line growth to drive EBITDA over time ~$1.9–$2.0M contribution to YoY growth; renewals skew to H2 Continued contribution to revenue growth and analytics capabilities Positive momentum
HEOR projectsExpanding services; project-based solutions Strong pipeline; high win rate “Meaningful growth” via new integrations, renewals, expanded scopes Strengthening
Data supply contracts/integrationAccelerated vendor integrations post-2024 disruptions Expanded coverage; advanced normalization/cleansing Ongoing selective investment to enhance data quality and utility Ongoing buildout
Macro/pharma spendingSome FDA-related timing impacts; generally insulated Mixed spending environment; cautious pharma Continued adoption of real-world data by life sciences and services clients Mixed but supportive
M&A strategyAccretive, strategic deals sought Smaller target valuations moderating; active pipeline Continued strategic focus; no update on take-private offer Active/discipline
AI/productivityEmerging in delivery/products; predictive models in Kyber Investigating AI agents for engineering efficiency; HIPAA constraints Emphasis on predictive analytics accuracy vs consensus Gradual adoption

Industry context press release (market BI expansion, AI integration) supports secular demand tailwinds for healthcare analytics providers .

Management Commentary

  • “Forian delivered another solid quarter characterized by disciplined execution, expanding client engagement, and ongoing operational improvement. We remain focused on driving sustainable growth, enhancing profitability, and strengthening our position…” .
  • “Revenue for the third quarter was $7.76 million, an increase of 66% year over year, primarily reflecting contributions from the Kyber Data Science acquisition and the continued expansion in health economics and outcomes research projects.” .
  • “We ended the period with $28.2 million of cash and marketable securities and $29.2 million of working capital… our convertible notes matured on September 1, 2025, and were fully repaid.” .
  • Non-GAAP framing: Adjusted EBITDA excludes stock-based comp, D&A, interest income/expense, litigation, transaction-related, contract termination impacts, and tax; reconciliation provided in the release .

Q&A Highlights

  • Q2: H2 performance depends on Kyber annual renewals; acquisition pipeline active as valuations moderate; organic growth led by HEOR and Kyber; EBITDA range depends on both revenue and discretionary investments in data assets/products .
  • Q2: AI productivity gains under evaluation for engineering; delivery side already leverages AI in Kyber; HIPAA constraints temper ingestion-side adoption .
  • Q1: Kyber revenue model 1-year SaaS; EBITDA progression tied to top-line scaling; bifurcated M&A market with more accretive opportunities as VC valuations reset .
  • Q3: No analyst questions on the call; management reiterated high-end guidance bias .

Estimates Context

  • Revenue beat: $7.76M actual vs $7.26M estimate — ~+$0.50M differential; indicates stronger demand and/or faster execution than modeled by the single covering analyst .
  • EPS beat: +$0.021 actual vs -$0.04 estimate — a meaningful surprise; note company-reported GAAP net loss and $0.00 EPS rounding; the S&P “Primary EPS” may reflect a different calculation basis and rounding conventions .
  • With high-end FY25 guidance reaffirmed, estimates likely bias upward for both revenue and adjusted EBITDA into Q4; renewal timing and discretionary data/product investments remain the principal swing factors .

Values retrieved from S&P Global.*

Key Takeaways for Investors

  • Sustained top-line momentum (Q1–Q3) with Q3 revenue/EPS beats and reaffirmed high-end FY25 guidance is supportive for near-term estimate revisions and sentiment .
  • Balance sheet de-risked via full note repayment; $28.2M cash + marketable securities provides flexibility for data acquisitions and selective M&A to extend product reach and client penetration .
  • Growth drivers are durable: HEOR expansion, improved data coverage/integrations, and Kyber’s predictive analytics for financial clients; these underpin multi-vertical diversification and potential margin leverage .
  • Watch H2 renewal cadence for Kyber and management’s discretionary investments in data assets; these determine whether adjusted EBITDA lands at the high end vs mid/low end of the range .
  • Non-GAAP reliance remains material; monitor stock-based compensation and data costs as recurring headwinds and assess progress in aligning GAAP profitability over time .
  • Macro caution persists in pharma budgets, but secular adoption of real-world data and AI-enhanced analytics supports medium-term thesis for Forian’s data products .
  • Near-term trading: positive skew given the beat and high-end guidance rhetoric; medium-term thesis rests on execution in renewals, expanding HEOR, and integrating Kyber’s models/products to drive scalable profitability .